Last reviewed · How we verify
NCT05024526
Protective Effects of Edaravone Dexborneol
NA trial testing edaravone dexborneol or edaravone in Acute Ischemic Stroke in 80 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Lili Cao |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 April 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- edaravone dexborneol or edaravone — full drug profile →
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Lili Cao — full company profile →
Who can join
Adults 50 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of imaging and the improvement of NIHSS and mRS in different groups.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neuroprotective Strategies for Ischemic Stroke-Future Perspectives.
Haupt M, Gerner ST, Bähr M, Doeppner TR. · · 2023 · cited 112× · PMID 36901765 · DOI 10.3390/ijms24054334 -
The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke.
Wicks EE, Ran KR, Kim JE, Xu R, et al · · 2022 · cited 68× · PMID 35795678 · DOI 10.3389/fimmu.2022.897022
Verify or expand the search:
- PubMed search for NCT05024526
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other Lili Cao trials
Trials by the same sponsor.
- NCT04996953 — The Correlation Study of Hypnotic Drugs on the Cognitive Function of Patients With Chronic Insomnia. · unknown
- NCT05003869 — Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions · NA · unknown
- NCT05000593 — Clinical Study of Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Knee Osteoarthritis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05024526 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lili Cao
- Last refreshed: 13 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05024526.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing